Article

Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus.

Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.
Vaccine (impact factor: 3.77). 10/2009; 28(17):3047-54. DOI:10.1016/j.vaccine.2009.10.072
Source: PubMed

ABSTRACT Bluetongue virus causes an emerging disease of ruminants, principally affecting sheep and cattle. Since 1998, there have been multiple separate outbreaks of bluetongue disease in Europe that have highlighted the need for a safe, efficacious, DIVA compliant vaccine. We report here a new baculovirus expression strategy which allowed pre-integration of the genes encoding the BTV inner capsid proteins at one baculovirus locus and those encoding the outer capsid proteins at a different locus. A modified baculovirus with two marker proteins to facilitate the phenotypic selection of recombinant viruses was developed. The utility of this approach is demonstrated by the production of BTV VLPs to a number of serotypes. For a proof of concept, VLPs of one serotype was then tested for protective immune response. VLPs were demonstrated to be safe, highly effective, immunogens in sheep, reducing post-challenge viraemia to levels below the threshold detection limit of quantitative RT-PCR when vaccinated animals were challenged with virulent virus.

0 0
 · 
0 Bookmarks
 · 
40 Views
  • Article: Formulation and delivery of vaccines: Ongoing challenges for animal management.
    Sameer Sharma, Lyn A Hinds
    [show abstract] [hide abstract]
    ABSTRACT: Development of a commercially successful animal vaccine is not only influenced by various immunological factors, such as type of antigen but also by formulation and delivery aspects. The latter includes the need for a vector or specific delivery system, the choice of route of administration and the nature of the target animal population and their habitat. This review describes the formulation and delivery aspects of various types of antigens such as killed microorganisms, proteins and nucleic acids for the development of efficacious and safe animal vaccines. It also focuses on the challenges associated with the different approaches that might be required for formulating and delivering species specific vaccines, particularly if their intended use is for improved animal management with respect to disease and/or reproductive control.
    Journal of Pharmacy & Bioallied Sciences 10/2012; 4(4):258-66.
  • Source
    Article: Characterization of the immune response induced by a commercially available inactivated bluetongue virus serotype 1 vaccine in sheep.
    Ana Cristina Pérez de Diego, Pedro José Sánchez-Cordón, Ana Isabel de las Heras, José Manuel Sánchez-Vizcaíno
    [show abstract] [hide abstract]
    ABSTRACT: The protective immune response generated by a commercial monovalent inactivated vaccine against bluetongue virus serotype 1 (BTV1) was studied. Five sheep were vaccinated, boost-vaccinated, and then challenged against BTV1 ALG/2006. RT-PCR did not detect viremia at any time during the experiment. Except a temperature increase observed after the initial and boost vaccinations, no clinical signs or lesions were observed. A specific and protective antibody response checked by ELISA was induced after vaccination and boost vaccination. This specific antibody response was associated with a significant increase in B lymphocytes confirmed by flow cytometry, while significant increases were not observed in T lymphocyte subpopulations (CD4(+), CD8(+), and WC1(+)), CD25(+) regulatory cells, or CD14(+) monocytes. After challenge with BTV1, the antibody response was much higher than during the boost vaccination period, and it was associated with a significant increase in B lymphocytes, CD14(+) monocytes, CD25(+) regulatory cells, and CD8(+) cytotoxic T lymphocytes.
    TheScientificWorldJOURNAL 01/2012; 2012:147158. · 1.66 Impact Factor
  • Source
    Article: Review Article Use of Bacterial Artificial Chromosomes in Baculovirus Research and Recombinant Protein Expression: Current Trends and Future Perspectives
    Polly Roy, Rob Noad
    [show abstract] [hide abstract]
    ABSTRACT: The baculovirus expression system is one of the most successful and widely used eukaryotic protein expression methods. This short review will summarise the role of bacterial artificial chromosomes (BACS) as an enabling technology for the modification of the virus genome. For many years baculovirus genomes have been maintained in E. coli as bacterial artificial chromosomes, and foreign genes have been inserted using a transposition-based system. However, with recent advances in molecular biology techniques, particularly targeting reverse engineering of the baculovirus genome by recombineering, new frontiers in protein expression are being addressed. In particular, BACs have facilitated the propagation of disabled virus genomes that allow high throughput protein expression. Furthermore, improvement in the selection of recombinant viral genomes inserted into BACS has enabled the expression of multiprotein complexes by iterative recombineering of the baculovirus genome.
    ISRN Microbiology. 01/2012; 11.

Show more

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

allowed pre-integration
 
baculovirus locus
 
bluetongue disease
 
BTV inner capsid proteins
 
BTV VLPs
 
DIVA compliant vaccine
 
emerging disease
 
marker proteins
 
modified baculovirus
 
new baculovirus expression strategy
 
outer capsid proteins
 
phenotypic selection
 
post-challenge viraemia
 
protective immune response
 
quantitative RT-PCR
 
recombinant viruses
 
threshold detection limit
 
virulent virus
 
VLPs